Figure 3.

CD14bright/CD56+ monocyte subset decreases during therapeutic tumor necrosis factor blockade. (a) Peripheral blood frequencies of CD14bright/CD56+ monocytes in 16 RA patients before and after treatment with etanercept. (b) Change in Disease Activity Score in 28 joints (∆DAS28) and CD14bright/CD56+ monocyte frequency at week 12 of treatment with etanercept (Enbrel) correlated to baseline (n = 16).

Krasselt et al. Arthritis Research & Therapy 2013 15:R139   doi:10.1186/ar4321
Download authors' original image